| |
Success or failure of a therapeutic program will depend on the understanding of the market and ability to develop an effective commercial strategy. Download our checklist to gain these insights and learn how Premier Consulting can evaluate the market and maximize the potential of your program throughout the development lifecycle.
|
|
Today’s Big NewsJun 6, 2024 |
|
September 30- October 1, 2024| Boston, MA The Fierce New Product Planning Summit is the only conference focused on how life science professionals make informed, value-based, data-driven decisions about pipeline products. Experts gather annually to discuss resource utilization and key questions for commercial success. Stay Updated!
|
|
| By Annalee Armstrong The docs for Eli Lilly’s donanemab advisory committee meeting are in: the FDA has raised concerns about the use of tau PET imaging during the clinical trials, the cessation of dosing after amyloid clearance and whether the small risk of brain bleeds in patients taking antithrombotics outweighs the benefits. |
|
|
|
By Nick Paul Taylor After taking 11 months to get to know Elsie Biotechnologies' oligonucleotide platform, GSK is ready to tie the knot with a $50 million deal to acquire the West Coast biotech. |
By Gabrielle Masson Biopharma investment trends continue to shift, with venture funding jumping to $7.4 billion across 188 deals for the first quarter of the year. This compares to $6.3 billion across 248 deals the previous quarter and demonstrates an increase in deal value despite declining deal count, according to PitchBook. |
Sponsored by Altasciences Discover the increasing body of evidence that supports the use of miniature swine as a viable non-rodent option for nonclinical studies. |
By Helen Floersh The contract research organization and pharma giant will work on a new project that will see virtual control animals take the place of live ones in preclinical research. |
By Fraiser Kansteiner Back in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in patients with fatty liver disease. Now, the company is laying out the fine details. |
By Conor Hale It’s all systems go for Moon Surgical with a new FDA green light for its Maestro robotic laparoscopy platform. |
By Kevin Dunleavy Doxycycline, an antibiotic widely used to combat acne, malaria and Lyme disease, has been recommended by the CDC for use in the United States by gay and bisexual men and transgender women after having unprotected sex to ward off sexually transmitted infections. |
By Fraiser Kansteiner In an eight-observation Form 483, the FDA chided Hengrui for a laundry list of manufacturing missteps, including poor contamination controls, subpar cleaning protocols, failure to promptly hand over documentation to inspectors and quality control shortfalls. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," two journalists from the Fierce Biotech team share key insights from their four-part series on the challenges and breakthroughs in cell therapy. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $200 when you register today!
|
|
| WebinarWatch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| WhitepaperThis detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
